Trials / Terminated
TerminatedNCT02443337
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3023414 | Administered orally |
| DRUG | Necitumumab | Administered IV |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2015-05-13
- Last updated
- 2020-12-09
- Results posted
- 2020-12-09
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02443337. Inclusion in this directory is not an endorsement.